Monday, October 3, 2022


Biotechnology News Magazine

Results from a Double-blind Randomized Controlled Trial of Scallop-derived Plasmalogens Published in Frontiers in Cell and Developmental Biology

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

The Japanese Plasmalogen Society (Office: Higashi-ku, Fukuoka, Japan; President: Yutaka Oomura) announced the research results that scallop-derived plasmalogens administered to college athletes improved sleep disorders, negative mood and mental concentration.

Plasmalogens, a class of phospholipids, serve vital roles in the body, including antioxidant action, ion transport, cholesterol efflux and membrane fusion. Plasmalogens are known to protect the brain against oxidative damage, and to activate brain function. Notably, scallop-derived plasmalogens, compared to sea squirt- and chicken-derived plasmalogens, abundantly contain DHA-rich plasmalogens, which have been found to be more effective for cognitive function than other types of plasmalogens in the previous studies.

The research team led by Dr. Takehiko Fujino, Professor emeritus of Kyushu University, revealed significant improvements in the plasmalogen-treated group compared to the placebo group by conducting a RCT.

Key findings are as follows: 1. Sleep problems were significantly alleviated. 2.“Anger-Hostility” and “Fatigue-Inertia” of the mood scale were significantly improved. 3. Mental concentration was boosted.

Sleep disorders assessed by the Athens Insomnia Scale were significantly improved in the plasmalogen-treated group while no such improvement was found in the placebo group. There were significant improvements in Anger-Hostility and Fatigue-Inertia of Profile of Mood States 2 (POMS2) in the plasmalogen-treated group, but not in the placebo group. Study participants with stronger negative moods showed more marked improvement. The plasmalogen-treated group showed a continuous improvement in the scores of the Uchida-Kraepelin test during the tests, while the placebo group showed the slowing down in the scores at min 5.

Mental concentration is a crucial factor that often determines the success or failure of study, work and sports. Poor concentration is one of the symptoms of mental illness such as depression. The research results have shown that orally administered scallop-derived plasmalogens markedly improve a stronger negative mood and then enhance mental concentration in athletes. This suggests that scallop-derived plasmalogens would be useful for anyone who hopes to be free from a negative mood and to be lively.

These findings were published in Frontiers in Cell and Developmental Biology, a leading, open-access, peer-reviewed scientific journal (Impact Factor 6.684).

Article Title: Orally Administered Plasmalogens Alleviate Negative Mood States and Enhance Mental Concentration: A Randomized, Double-Blind, Placebo-Controlled Trial.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine